# Jasper Therapeutics, Inc. (JSPRW) — merger [announced]
Source: SEC API (secapi.ai) · situation sit_1014a08abe5dd313afe7 · retrieved 2026-08-11T15:50:51.468Z

## Overview
Jasper Therapeutics, Inc. is a Delaware corporation engaged in the acquisition and development of pharmaceutical assets, including the acquisition of Kira Pharmaceuticals and its briquilimab program.

Jasper Therapeutics, Inc. completed its acquisition of Kira Pharmaceuticals, a Cayman Islands exempted company, pursuant to an Agreement and Plan of Merger dated July 16, 2026. Each shareholder of Jasper common stock as of the closing date received one contingent value right (CVR) per share. The CVRs entitle holders to receive a pro rata portion of $30.0 million if the U.S. Food and Drug Administration issues a Priority Review Voucher for briquilimab on or before December 31, 2028. If the milestone is achieved and a Change of Control occurs, the payment is due on the earlier of the change-of-control date or 90 days after a Monetization Event. If the milestone is achieved but no Monetization Event has occurred by the expiration date, the CVRs remain in effect until the payment is made.

## Terms
- Counterparty: Kira Pharmaceuticals · Deal value: $30.0M

## Key dates
- Announced 2026-07-31 · Record 2026-07-16 · Expiry 2028-12-31

## Timeline
- 2026-07-31 · 8-K (0001213900-26-083563): 8-K - Jasper Therapeutics, Inc. — *Jasper Therapeutics, Inc. is a Delaware corporation engaged in the acquisition and development of pharmaceutical assets, including the acquisition of Kira Pharmaceuticals and its briquilimab program.* Jasper Therapeutics, Inc. completed its acquisition of Kira Pharmaceuticals, a Cayman Islands exempted company, pursuant to an Agreement and Plan of Merger dated July 16, 2026. Each shareholder of Jasper common stock as of the closing date received one contingent value right (CVR) per share. The CVRs entitle holders to receive a pro rata portion of $30.0 million if the U.S. Food and Drug Administration issues a Priority Review Voucher for briquilimab on or before December 31, 2028. If the milestone is achieved and a Change of Control occurs, the payment is due on the earlier of the change-of-control date or 90 days after a Monetization Event. If the milestone is achieved but no Monetization Event has occurred by the expiration date, the CVRs remain in effect until the payment is made.
  https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-083563.txt

## Citations
- 0001213900-26-083563 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026083563